THERAVLINFO is a collaborative project aimed at improving the survival and quality of life of patients with non-Hodgkin lymphoma (NHL). It builds on the previous IMLINFO project, focusing on the development and translation of knowledge and preclinical models. THERAVLINFO is a multidisciplinary network that seeks to strengthen cooperation between 4 previous partners (2 hospitals and 2 research centers, in Barcelona and Toulouse) and foster new synergies with a research center in Navarra. Moreover, collaborates with 2 biotech companies in the POCTEFA territory.

THERAVLINO is the evolution of its precedent project IMLINFO, where the consortium established a repository of samples from NHL patients and developed a 3D culture platform to mimic the disease in vitro. It also created a workflow for high-throughput screening of antitumor drugs. Through this work, specific targets related to immune evasion and immunosuppression were identified. THERAVLINFO aims to further improve these 3D culture systems, develop drugs targeting these identified targets (antibodies, cell therapy and nanocapsules), and validate their therapeutic potential using l NHL murine models. The project brings together experts in various fields, including multicellular 3D cultures, animal models, cytometry, microscopy, omics technologies, and computational analysis. It also emphasizes the training of young researchers who can rotate among the different partners to gain expertise.

Additionally, THERAVLINFO develops cell therapies thanks the CAR-T program at Hospital Clinic de Barcelona, and collaborates with biotech companies to develop antibody-based immunotherapies (ONA Therapeutics) and new delivery systems for antibodies (NUCAPS) to allow oral administration systems. The ultimate goal of THERAVLINFO is to advance personalized medicine for NHL patients who do not respond to standard treatment, experience early relapses, or develop aggressive lymphoma. The cross-border cooperation is crucial for obtaining patient material from hospitals in the POCTEFA territory and to develop novel therapies in NHL.